Lazard Asset Management LLC Invests $61,000 in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,098 shares of the company’s stock, valued at approximately $61,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $355,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Kiniksa Pharmaceuticals by 36.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock valued at $2,414,000 after purchasing an additional 32,393 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $3,955,000. Globeflex Capital L P boosted its holdings in Kiniksa Pharmaceuticals by 217.1% during the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock worth $1,752,000 after buying an additional 60,656 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock valued at $15,262,000 after buying an additional 29,300 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $510,815.50. This trade represents a 61.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Michael R. Megna sold 9,051 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. This trade represents a 25.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 243,640 shares of company stock valued at $5,986,056 in the last 90 days. 54.57% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Finally, Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $38.80.

Kiniksa Pharmaceuticals Trading Up 3.6%

KNSA stock opened at $26.89 on Monday. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $28.56. The business’s 50-day moving average is $23.26 and its 200 day moving average is $21.48. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -192.06 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same period in the previous year, the company posted ($0.25) earnings per share. The business’s revenue was up 72.5% on a year-over-year basis. As a group, equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.